In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary

Michael Hutchinson

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Access to Document

@article{349e5ba6eba24cceb53e88ca8d5aa66a,

title = "In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary",

author = "Michael Hutchinson",

year = "2013",

month = jan,

doi = "10.1177/1352458512470507",

language = "English",

volume = "19",

pages = "29--30",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "1",

}

TY - JOUR

T1 - In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS

T2 - Commentary

AU - Hutchinson, Michael

PY - 2013/1

Y1 - 2013/1

UR - https://www.scopus.com/pages/publications/84872329963

U2 - 10.1177/1352458512470507

DO - 10.1177/1352458512470507

M3 - Article

AN - SCOPUS:84872329963

SN - 1352-4585

VL - 19

SP - 29

EP - 30

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 1

ER -